Flatley Discovery Lab LLC
9
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.4% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
A DDI Study of FDL169 and FDL176 in Healthy Subjects
Role: lead
An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects
Role: lead
A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects
Role: lead
A Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects
Role: lead
A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants
Role: lead
A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects
Role: lead
Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis
Role: lead
FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers
Role: lead
Pharmacokinetics of FDL169 in Healthy Female Subjects
Role: lead
All 9 trials loaded